title: Radioprotection of craniofacial bone growth.
abstract: In this review, the potential of pharmacologic therapy for prevention of radiation-induced bone growth inhibition is discussed. Significant radioprotection using the radioprotector Amifostine has been achieved in animal models of radiation-induced retardation of long and craniofacial bone growth. Moreover, radioprotection in vitro has been achieved in a number of cell lines, including osteoblast-like, endothelial, and fibroblastic. This evidence may support future clinical investigations of radioprotector Amifostine or similar substances for radioprotection of the growing craniofacial skeleton.
authors.affiliation: Division of Plastic Surgery, Hospital for Sick Children, Toronto, Canada.
authors.forename: Artur
authors.initials: A
authors.lastname: Gevorgyan
authors.forename: Giorgio C
authors.initials: GC
authors.lastname: La Scala
authors.forename: Peter C
authors.initials: PC
authors.lastname: Neligan
authors.forename: Cho Y
authors.initials: CY
authors.lastname: Pang
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Forrest
mesh_terms: D004999:Amifostine / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D001842:Bone and Bones / Q000187:drug effects / Q000528:radiation effects; D002460:Cell Line / Q000187:drug effects / Q000528:radiation effects; D005147:Facial Bones / Q000187:drug effects* / Q000254:growth & development / Q000528:radiation effects; D006128:Growth / Q000528:radiation effects; D023421:Models, Animal; D011833:Radiation Injuries, Experimental / Q000517:prevention & control; D011835:Radiation Protection / Q000379:methods*; D011837:Radiation-Protective Agents / Q000378:metabolism / Q000494:pharmacology*; D011878:Radiotherapy / Q000009:adverse effects
chemical_list: D011837:Radiation-Protective Agents; D004999:Amifostine